|Bid||0.65 x 0|
|Ask||0.67 x 0|
|Day's Range||0.63 - 0.67|
|52 Week Range||0.19 - 1.13|
|PE Ratio (TTM)||-5.00|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.19|
By John Vandermosten, CFA OTC:ONCYF TSX:ONC.V Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a successful end of Phase II meeting with the FDA in a September 18 press release. The purpose of the ...
CALGARY and SAN DIEGO, Sept. 19, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that it will present at the Phacilitate Immuno-Oncology Frontiers Conference. Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and 21st in Berlin, Germany.
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference